Local estrogen replacement therapy in postmenopausal atrophic vaginitis: Efficacy and safety of low dose 17β-estradiol vaginal tablets

G. Mainini, C. Scaffa, M. Rotondi, E. M. Messalli, L. Quirino, A. Ragucci

Research output: Contribution to journalArticle

Abstract

Purpose of investigation: To verify the effectiveness and safety of low-dose 17β-estradiol vaginal tablets in the treatment of the postmenopausal atrophic vaginitis. Patients and methods: 325 postmenopausal women with atrophic vaginitis in estrogenic replacement therapy with 0.025 mg 17β-estradiol vaginal tablets, one application each day for two weeks, and a single application two times a week for the following 22 weeks (total treatment period: 24 weeks). Results: Most of the women reported an improvement of symptoms just after two weeks and minimal incidence of adverse reactions. No patients showed abnormal endometrial thickness and no one had to interrupt the treatment for abnormal uterine bleeding because of systemic absorption. Conclusion: Low-dose 17β-estradiol vaginal tablets in the treatment of the postmenopausal atrophic vaginitis constitutes an extremely valid approach in terms of effectiveness and safety.

Original languageEnglish
Pages (from-to)111-113
Number of pages3
JournalClinical and Experimental Obstetrics and Gynecology
Volume32
Issue number2
Publication statusPublished - 2005

Keywords

  • 17β-estradiol vaginal tablets
  • Atrophic vaginitis
  • Estrogen replacement therapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Local estrogen replacement therapy in postmenopausal atrophic vaginitis: Efficacy and safety of low dose 17β-estradiol vaginal tablets'. Together they form a unique fingerprint.

  • Cite this